Background
Disease activity assessments
Birmingham Vasculitis activity score
Pediatric Vasculitis activity score
Disease damage assessments
Treatment overview
Study Group | Clinical Subgroup | Systemic Vasculitis Outside Ears, Nose, Throat and Lungs | Threatened Vital Organ Function | Other Definitions | Serum Creatinine (umol/L) |
---|---|---|---|---|---|
EUVAS | Localized | No | No | No constitutional symptoms, ANCA typically negative | < 120 |
Early Systemic | Yes | No | Constitutional symptoms present, ANCA-positive or negative | < 120 | |
Generalized | Yes | Yes | ANCA-positive | < 500 | |
Severe | Yes | Organ Failure | ANCA-positive | > 500 | |
Refractory | Yes | Yes | Refractory to standard therapy | Any | |
WGET Research Group | Limited | Allowed, but not required | No | Not severe | < 124, if hematuria, but no red blood cell casts present |
Severe | Yes | Yes | Organ- or life-threatening disease | Any |
Induction trials
Induction trials for severe disease
Reference, Country | Study Design | Patient Selection | Experiment | Comparators | Primary Outcome | Results | Adverse Events |
---|---|---|---|---|---|---|---|
NORAM, Groot et al., 2005, Germany | Unblinded, prospective RCT | GPA or MPA limited/non-severe disease | MTX PO 15 mg/week escalated to a maximum of 20–25 mg/week by 12 weeks, until month 10, then tapered and discontinued by month 12 Prednisone 1 mg/kg/day, tapered to 7.5 mg by 6 months, discontinued by 12 months | CYC PO 2 mg/kg/day (maximum 150 mg/day) × 3–6 months until remission then 1.5 mg/kg to month 10, then tapered and discontinued by month 12 Prednisone 1 mg/kg/day, tapered to 7.5 mg by 6 months, discontinued by 12 months | Remission within 6 months | MTX (89.8%) CYC (93.5%) | 83 patients: adverse events 68 patients: mild/moderate infection 15 patients: severe infection MTX: liver toxicity (p 0.036) CYC: leukopenia (p 0.012) |
MEPEX, Jayne et al., 2007, Europe | RCT | GPA, MPA with severe renal vasculitis | PLEX 60 ml/kg for 7 cycles within 14 days CYC PO 2.5 mg/kg/day, reduced to 1.5 mg/kg/day at 3 months and discontinued at 6 months Prednisone 1 mg/kg/day tapered until 10 mg/day from 5 to 12 months | Pulse GC 1 g for 3 days CYC PO 2.5 mg/kg/day, reduced to 1.5 mg/kg/day at 3 months and discontinued at 6 months Prednisone 1 mg/kg/day tapered until 10 mg/day from 5 to 12 months | Renal recovery at 3 months | PLEX 69% IV GC 49% | No difference between 2 groups PLEX: 50% Pulse GC: 48% |
CYCLOPS, Groot et al., 2009, Europe | Open label RCT | GPA, MPA, renal limited MPA (GFR < 500) | CYC IV pulses 15 mg/kg, given 2 weeks apart, followed by pulses at 3-week interval until remission, and then for 3 months Prednisone 1 mg/kg/day tapered to 12.5 mg by 3 months then 5 mg at 18 months | CYC PO 2 mg/kg/day until remission, followed by 1.5 mg/kg/day for 3 months Prednisone 1 mg/kg/day tapered to 12.5 mg by 3 months then 5 mg at 18 months | Time to remission | 87.9% achieved remission by 9 months (no difference between the two groups, 88% in the IV group, 87.7% in the PO group) Relapses: CYC IV: 13 patients CYC PO: 6 patients CYC IV: lower cumulative dose (p 0.001) | IV group: less leukopenia (26% vs 45%) Death: CYC IV: 5 patients CYC PO: 9 patients No difference in the rate of life threatening events |
RITUXVAS, Jones et al., 2010, Europe/Australia | Open label RCT | Newly diagnosed AAV with evidence of renal involvement | RTX, 375 mg/m2 weekly for 4 weeks plus CYC IV 15 mg/kg with 1st and 3rd dose Pulse GC 1 g, followed by prednisone 1 mg/kg/day, tapered to 5 mg by 6 months | CYC IV 15 mg/kg every 2 weeks for the first 3 doses then every 3 weeks, until remission (3–6 months) then AZA 2 mg/kg to end of study (12 months) prednisone 1 mg/kg/day, tapered to 5 mg by 6 months | Sustained remission at 12 months Time to remission | RTX was not superior to CYC. Sustained remission: RTX: 76% CYC: 82% Median time of remission: RTX: 90 days CYC: 94 days | Similar rate of adverse events RTX: 42% CYC: 36% Similar death rate in both groups: 18% |
RAVE, Stone et al., 2010, USA | Double blinded RCT | Severe AAV (period of 6 months) | RTX 375 mg/m2 weekly for 4 weeks then placebo AZA for 18 months Pulse GC 1 g for 1–3 doses followed by prednisone 1 mg/kg/day, discontinued by 5 months | CYC PO 2 mg/kg/day until remission (3–6 months) then AZA for 18 months Pulse GC 1 g for 1–3 doses followed by prednisone 1 mg/kg/day, discontinued by 5 months | Disease remission off steroids by 5 months | RTX was not inferior to CYC. RTX regimen was superior to CYC in inducing remission in previously relapsing disease | No difference in the number of adverse events CYC higher rate for leukopenia (10% vs 3%) |
MYCYC, Jones et al., 2019, UK | Open label RCT | Newly diagnosed AAV, non- life threatening | MMF 2–3 g (BSA dose for patients < 17 years old) Prednisone 1 mg/kg/day tapered to 5 mg by 6 months | CYC IV 15 mg/kg, given 2 weeks apart, followed by pulses at 3-week intervals until remission, and then for 3 months Prednisone 1 mg/kg/day tapered to 5 mg by 6 months | Remission by 6 months | MMF (67%) was not inferior to IV CYC (61%). Relapse rate higher in MMF (33%) vs IV CYC (19%) | No significant difference in serious adverse events between two groups MMF (50%) IVCYC (40%) |
Induction trials for limited disease
Maintenance trials
Reference, Country | Study Design | Patient Selection | Induction | Experiment | Comparators | Primary Outcome | Results | Adverse Events |
---|---|---|---|---|---|---|---|---|
CYCAZAREM, Jayne et al., 2003, Europe | Open label RCT | Newly diagnosed GPA, MPA, renal-limited vasculitis (serum Cr < 500 μmol/L) | CYC PO and GC | AZA 2 mg/kg/day, tapered to 1.5 mg/kg/day at month 12, and discontinued at month 18 and Prednisolone 10 mg/day until month 12, tapered to 7.5 mg/day until month 18 | CYC PO 1.5 mg/kg/day until month 12 then AZA 1.5 mg/kg/day until month 18 and Prednisolone 10 mg/day until month 12, tapered to 7.5 mg/day until month 18 | Relapse rate (major and minor) | 15.5% in AZA, 13.7% in CYC (p 0.65) | - Severe AEs: 11% in AZA, 10% in CYC (p 0.94) |
Metzler et al., 2007, Germany | Open label RCT | Generalized GPA Serum Cr < 115 μmol/L | CYC PO and GC | LEF 100 mg for 3 days, followed by 20 mg/day until week 4 then 30 mg/day and Prednisolone 10 mg/day or below and tapered by 2.5 mg/month until 5 mg and by 1 mg/month thereafter | MTX PO 7.5 mg/week, gradually increased to 20 mg/week after week 8 and Prednisolone 10 mg/day or below and tapered by 2.5 mg/month until 5 mg and by 1 mg/month thereafter | Relapse rate (major and minor) | 23% in LEF, 46% in MTX (p 0.09) | - No difference of AEs in LEF and MTX - 15% in LEF were withdrawn: hypertension, leukopenia, peripheral neuropathy |
WEGENT, Pagnoux et al., 2008, France | Open label RCT | Newly diagnosed GPA or MPA with systemic involvement | CYC IV and GC | AZA 2 mg/kg/day for 12 months then withdraw over 3 months and Prednisolone 12.5 mg at 6 months and tapered to 5 mg/day at 18 months and discontinued at month 24 | MTX 0.3 mg/kg, increased every week to 25 mg/week for 12 months then withdraw over 3 months and Prednisolone 12.5 mg at 6 months and tapered to 5 mg/day at 18 months and discontinued at month 24 | AEs causing death or drug discontinuation | 11% in AZA, 19% in MTX (p 0.21) Death: 1 in MTX (hematotoxicity and sepsis) Relapse: 36% in AZA vs 33% in MTX (p 0.71) | - Any AEs: 46% in AZA, 56% in MTX (p 0.29) |
IMPROVE, Hiemstra et al., 2010, Europe | Open label RCT | Newly diagnosed GPA, MPA | CYC PO/IV and GC ± PLEX | MMF 2 g/day, reduced to 1.5 g/day after 12 months, 1 g/day after 18 months and discontinued after 42 months and Prednisolone until month 24 | AZA 2 mg/kg/day, reduced to 1.5 mg/kg after 12 months, 1 mg/kg after 18 months, and discontinued after 42 months and Prednisolone until month 24 | Relapse-free survival | 55% in MMF, 37.5% in AZA (p 0.03, HR 1.69) | - Severe AEs: 7.5% in MMF, 16% in AZA (p 0.12) - Death: 1 in MMF (fungal septicemia), 1 in AZA (sudden cardiac death) |
MAINRITSAN, Guillevin et al., 2014, France | Open label RCT | Newly diagnosed or relapsing GPA, MPA, renal-limited vasculitis | CYC IV and GC | RTX 500 mg at day 0, 14, month 6, 12, 18 Prednisone 5 mg/day for at least 18 months | AZA 2 mg/kg/day 12 months then 1.5 mg/kg 6 months, then 1 mg/kg 4 months Prednisone 5 mg/day for at least 18 months | Major relapse rate at 28 months | 5% in RTX, 29% in AZA (p 0.002, HR 6.61) Minor relapse: 11% in RTX, 16% in AZA (p 0.43) | - Severe AEs: no significant difference - Death: 2 in AZA (sepsis and pancreatic cancer) |
REMAIN, Karras et al., 2017, Europe | Open label RCT | GPA, MPA, renal-limited vasculitis | CYC and GC ± PLEX | Continuation group: AZA 1 mg/kg/day to end of study and prednisolone 5 mg/day for 12 months then tapered and discontinued by 24 months | Withdrawal group: AZA 0.75 mg/kg/day for 3 months and prednisolone 5 mg/day, tapered and discontinued by month 5 | Relapse rate (major and minor) by 30 months | 63% in withdrawal group, 22% in continuation group (p < 0.0001, RR 2.84) No difference of relapse severity | - Severe AEs: 15% in continuation group, 6% in withdrawal group (p 0.13) |
MAINRITSAN2, Charles et al., 2018, France | Open label RCT | Newly diagnosed or relapsing GPA, MPA | GC and CYC, RTX or MTX | Individually tailored: RTX 500 mg at randomization and then reinfused based on CD19+ B lymphocytes and ANCA titers until month 18 and low-dose prednisone | Fixed-schedule: RTX 500 mg at day 0, 14, month 6, 12, 18 and low-dose prednisone | Relapse rate at month 28 | 17.3% in individually tailored group, 9.9% in fixed-schedule group (p 0.22) | - Severe AEs: 32.1% in individually tailored group, 38.3% in fixed-schedule group (p 0.51) |
BREVAS, Jayne et al., 2019 | Double blind RCT | Newly diagnosed or relapsing GPA, MPA with ANCA positivity | GC and either CYC or RTX | Belimumab IV 10 mg/kg and AZA 2 mg/kg/day and low-dose GC (≤10 mg/day) | Placebo and AZA 2 mg/kg/day and low-dose GC (≤10 mg/day) | Time to first protocol-specified event (BVAS ≥6, presence of ≥1 major BVAS, or receipt of prohibited medications for any reason) | 18.9% in belimumab, 21.2% in control (p 0.89) | - Serious AEs: 34% in belimumab, 30.8% in placebo |
Eosinophilic granulomatosis with Polyangiitis (EGPA)
Reference, Country | Study Design | Patient Selection | Experiment | Comparators | Primary Outcome | Results | Adverse Events |
---|---|---|---|---|---|---|---|
Induction Trials | |||||||
Guillevin et al., 1991, France | RCT | PAN or EGPA | Group A: GC (1 mg/kg/day for 1 month then tapered) and PLEX (12 exchanges in first 2 months) (n = 36) | Group B: GC only (1 mg/kg/day for 1 month then tapered) (n = 42) | Control of disease (Recovery, remission), or death | 78 patients (18 EGPA patients) Primary Outcomes: Complete remission: 27 in group A, 29 in group B Relapse: 10/36 in group A, 8/42 in group B Death: 6 in group A, 9 in group B. No significant difference in 7 year cumulative survival rates | Deaths part of primary outcome |
Guillevin et al., 1995, France | RCT | Severe PAN or EGPA with features of poor prognosis | Additional use of PLEX: GC (15 mg/kg/day IV for 3 days, then PO 1 mg/kg/day for 1 month with tapering) and IV CYC pulse (600 mg/m2 every month for a year) and PLEX (9 exchanges in 3 weeks) (n = 34) | GC (15 mg/kg/day IV for 3 days, then PO 1 mg/kg/day for 1 month with tapering) and IV CYC pulse (600 mg/m2 every month for a year) (n = 28) | Relapse or remission or death | 62 patients (14 EGPA patients) Primary Outcomes: Remission: 16 in no PLEX group, 22 in PLEX group Relapse: 4 (14%) in no PLEX group, 3 (9%) in PLEX group Death: 7 (25%) in no PLEX group, 4 (11.8%) in PLEX group | AEs in PLEX group: pulmonary TB in 3 patients, pneumonia in 3 patients, acute sigmoiditis in 1 patient, and septicemia in 2 patients |
Gayraud et al., 1997, France | RCT | Good prognosis PAN or EGPA | Group A: GC (1 mg/kg/day for 1 month, decreased by 2.5 mg every week until 10 mg/day. At 6 months, decreased by 1 mg/week) and oral CYC (2 mg/kg/day) for 12 months (n = 12) | Group B: GC (1 mg/kg/day for 1 month, decreased by 2.5 mg every week until 10 mg/day. At 6 months, decreased by 1 mg/week) and IV pulse CYC (600 mg/m2 every month for a year) (n = 13) | Complete remission rates | 25 patients (8 EGPA patients) Primary Outcome: Complete remission in 9 (75%) in Group A, 10 (77%) in Group B Secondary Outcomes: Relapses: 2 in each group Failures: 1 in each group | 10 patients in group A experienced AEs, 8 in group B experienced AEs |
Cohen et al., 2007, France | RCT | EGPA patients with features of poor prognosis |
Shorter CYC regimen:
GC (15 mg/kg/day IV for 3 days, then 1 mg/kg/day oral for 1 month followed by tapering) and 6 IV CYC pulses (600 mg/m2 every 2–4 weeks) (n = 23) | GC (15 mg/kg/day IV for 3 days, then 1 mg/kg/day oral for 1 month followed by tapering) and 12 IV CYC pulses (600 mg/m2 every 2–4 weeks) (n = 25) | Complete remission rates | 48 patients Primary Outcome: Complete Remission in 21 (91%) in 6 pulse group vs 21 (84%) in 12 pulse group (NS) Secondary Outcomes: Relapses:18 (86%) ha a relapse in the 6 pulse group, 13 (62%) had a relapse in the 12 pulse group Deaths: 2 patients died in each group | Similar AE between groups (13 patients in the 12-pulse group compared to 11 patients in the 6-pulse group) |
Ribi et al., 2008, France | RCT | EGPA patients without features of poor prognosis who had treatment failure or relapse on GC alone (could not taper below 20 mg or those who experienced relapse) | AZA (2 mg/kg/day) for 6 months (n = 8) | 6 IV CYC pulses (600 mg/m2 every 2–4 weeks) (n = 10) | Complete remission rates | 72 patients, but 19 patients met inclusion criteria Primary Outcome: 5 (50%) in the CYC group experienced remission, 7 (78%) in the AZA group achieved remission (NS) | CYC AE: Hemorrhagic cystitis (n = 1), Infertility (n = 1) AZA AE: Skin rash (n = 2), elevated LFTs (n = 1) |
Pagnoux et al., 2015, France | Nonblinded, RCT | ≥ 65 years old with new diagnosis of PAN, GPA, MPA, or EGPA | Shorter GC duration and lower CYC doses: GC for 9 months (started at 1 mg/kg/day and tapered) and six 500 mg IV CYC pulses every 2–3 weeks | 26 months of GC (3 additional pulses for consolidation before maintenance for at least 18 months) and 500 mg/m2 IV CYC pulses every 2–3 weeks | Occurrence of ≥ 1 SAE, including deaths from all causes, during the 3 years of follow-up | 104 patients (14 EGPA patients). Primary Outcome: 32 (60%) of the patients in the experimental arm had ≥ 1 SAE versus 40 (78%) of the patients in the conventional arm (p = 0.04). 9 (17%) in the experimental arm and 12 (24%) in the conventional arm died Secondary Outcomes: Remission not achieved in 6 (11%) in experimental arm, 7 (14%) in the conventional arm (p = 0.71) Relapse occurred in 20 (44%) in experimental arm, 41 (29%) in conventional arm | Part of the primary outcome of the study |
Puechal et al., 2017, France | RCT | EGPA, PAN, MPA without features of poor prognosis | AZA (2 mg/kg/day) and GC (1 mg/kg/day for 3 weeks then tapered) | Placebo and GC (1 mg/kg/day for 3 weeks then tapered) | Combined rate of remission induction failures and minor or major relapses at month 24 | 95 patients (51 EGPA patients) Primary Outcome: 22 (48%) in the AZA group and 24 (49%) in the placebo group met end point (NS) Secondary Outcomes: No difference in initial relapse rates, relapses | Similar AE and SAE between groups |
Wechsler et al., 2017, USA | RCT | Relapsing or refractory EGPA who received treatment for 4 weeks and on stable doses of GC | Mepolizumab 300 mg subcutaneous every 4 weeks plus standard care for 52 weeks (n = 68) | Placebo and standard care for 52 weeks (n = 68) | Accrued weeks of remission and proportion of participants in remission at weeks 36 and 48 | 136 patients Primary Outcomes: Accrued weeks of remission: 28% in Mepolizumab and 3% in placebo arm had > 24 weeks in accrued remission (significant) Proportion in remission at week 36 and 48: 32% in Mepolizumab and 3% in placebo group (significant) Secondary Outcomes: Remission failure: 47% failed in Mepolizumab group, 81% failed in placebo group | Similar AE between groups (Mepolizumab: 97%, Placebo: 94%). Serious AEs: Mepolizumab 18%, Placebo: 26% |
Maintenance Trials | |||||||
Koike et al., 2015, Japan | RCT | EGPA patients with chronic residual peripheral neuropathy after disease remission | Group A: IVIG (0.4 g/kg for 5 days) followed by placebo then placebo (n = 8) Group B: Placebo, followed by IVIG (0.4 g/kg for 5 days), then placebo (n = 8) Group C: Placebo, followed by placebo, then IVIG (0.4 g/kg for 5 days) (n = 7)
Treatments provided at 2 week intervals
| Amount of change in the MMT sum score 2 weeks after IVIG administration | 23 patients MMT change after IVIG: 7.13, significant increase when compared to baseline scores Scores were increased significantly after 4, 6, 8 weeks after observation | AE in 14 patients (61%). Headaches (n = 4) and elevated ALT (n = 3) were most common |
Pediatric considerations
Reference, Country | Study Design | Patient Selection | Induction therapy | Maintenance therapy | Therapy-related outcomes | Adverse Events |
---|---|---|---|---|---|---|
Akikusa et al., 2007, Canada | Retrospective 1984–2005 | n = 25 GPA 100% | GC 100% CYC 76% AZA 40% MTX 32% | n = 7* AZA (n = 3) MTX (n = 4) | 100% achieved remission (median 5 months, range 3–6 months) 75% relapse rate (median 10 months) | 12 hospitalizations in 5 patients for infections 0 malignancies 0 deaths |
Iudici et al., 2015, France | Retrospective | n = 35 GPA 71.4% EGPA 17.1% MPA 11.4% | GC 91.4% GC + IS 77.1% CYC IV 54.3% CYC PO 5.7% AZA 8.6% MTX 5.7% SZ 2.9% PLEX 2.9% | – | Inactive disease at last follow-up (n = 33, median 96 months): GPA 68.2% on treatment EGPA 100% on treatment (50% on GC + IS) MPA 100% on treatment (66.7% on GC + IS) Relapse rates: 76% overall (GPA 83%, EGPA 50%, MPA 33%) | 9 infections 1 pancreatitis (GC) 2 cataracts (GC) 1 transaminitis (AZA) 1 hematologic (CYC) 1 hypertension (GC) 4 deaths |
Sacri et al., 2015, France | Retrospective 1986–2011 | n = 66 GPA 42% MPA 58% | GC 100% IV 86%, PO 14% CYC IV 47% CYC PO 20% RTX 13.6% MMF 4.5% PLEX 16.7% | GC alone 28.8% GC + AZA/ MTX/ MMF 63.6% AZA alone 1.5% None 6% | 92.4% achieved remission Post-induction: 70% achieved remission 24.2% (n = 16) had refractory disease; 15/16 achieved secondary remission with addition of CYC (n = 8), IVIG (n = 2), RTX (n = 3) PLEX (n = 3) 40.9% relapse rate (median 29 mos) | 4 deaths |
ARChiVe, Morishita et al., 2017, International | 2004–2007 retrospective, 2007–2008 prospective | n = 105 GPA 81% MPA 13% EGPA 6% | GC 100% (IV pulse 70%) CYC 70.5% MTX 16.2% RTX 13.3% AZA 1.9% MMF 1.0% PLEX 23.8% | AZA 42.3% MTX 22.8% MMF 13.3% CYC 9.5% RTX 9.5% None 4.7% | 44/105 (42%) achieved remission by 12 months 21/44 (48%) discontinued GC 41/44 (93%) remained on maintenance 24% relapse rate | 80 hospitalizations in 43 patients: 46% flares 16% infection 5% treatment-related 15% other disease-related 18% unrelated to vasculitis 0 deaths |